AR119549A1 - RECRUITMENT AGENT THAT ADDITIONALLY BINDS TO AN MHC MOLECULE - Google Patents
RECRUITMENT AGENT THAT ADDITIONALLY BINDS TO AN MHC MOLECULEInfo
- Publication number
- AR119549A1 AR119549A1 ARP200102162A ARP200102162A AR119549A1 AR 119549 A1 AR119549 A1 AR 119549A1 AR P200102162 A ARP200102162 A AR P200102162A AR P200102162 A ARP200102162 A AR P200102162A AR 119549 A1 AR119549 A1 AR 119549A1
- Authority
- AR
- Argentina
- Prior art keywords
- antigen
- binding proteins
- binding
- binds
- bispecific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente concierne a proteínas de unión a antígeno biespecíficas que están dirigidas contra antígenos diana (AD) que son presentados por el MHC. La misma proporciona en particular proteínas de unión a antígeno biespecíficas que comprenden al menos dos sitios de unión a antígeno (A y B), en las cuales el sitio de unión a antígeno A se une al CD3 y el sitio de unión a antígeno B se une a un complejo formado por el péptido antigénico diana y el MHC. Las proteínas de unión a antígeno biespecíficas de la presente comprenden, en particular, las CDR de los dominios VH y VL de anticuerpos genomodificados anti-CD3 dotados de una afinidad reducida. Las proteínas de unión a antígeno biespecíficas de la presente están destinadas al uso en el diagnóstico, el tratamiento y la prevención de enfermedades asociadas a AD, como las enfermedades cancerosas que expresan antígenos asociados a tumores (AAT). Además, se proporcionan ácidos nucleicos que codifican las proteínas de unión a antígeno biespecíficas de la misma, los vectores que comprenden esos ácidos nucleicos, las células recombinantes que expresan la proteína de unión de antígeno y las composiciones farmacéuticas que comprenden las proteínas de unión a antígeno biespecíficas de la presente.This concerns bispecific antigen-binding proteins that are directed against target antigens (AD) that are presented by the MHC. It provides in particular bispecific antigen-binding proteins comprising at least two antigen-binding sites (A and B), in which the antigen-binding site A binds to CD3 and the antigen-binding site B binds to CD3. binds to a complex formed by the target antigenic peptide and the MHC. The present bispecific antigen-binding proteins comprise, in particular, the CDRs of the VH and VL domains of gene-modified anti-CD3 antibodies endowed with reduced affinity. The present bispecific antigen-binding proteins are intended for use in the diagnosis, treatment, and prevention of AD-associated diseases, such as cancerous diseases that express tumor-associated antigens (TAAs). In addition, nucleic acids encoding the bispecific antigen-binding proteins thereof, vectors comprising those nucleic acids, recombinant cells expressing the antigen-binding protein, and pharmaceutical compositions comprising the antigen-binding proteins are provided. bispecific of the present.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102019121022.4A DE102019121022A1 (en) | 2019-08-02 | 2019-08-02 | Recruiting agent that also binds an MHC molecule |
Publications (1)
Publication Number | Publication Date |
---|---|
AR119549A1 true AR119549A1 (en) | 2021-12-29 |
Family
ID=74495302
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP200102162A AR119549A1 (en) | 2019-08-02 | 2020-07-31 | RECRUITMENT AGENT THAT ADDITIONALLY BINDS TO AN MHC MOLECULE |
Country Status (2)
Country | Link |
---|---|
AR (1) | AR119549A1 (en) |
DE (1) | DE102019121022A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115838432B (en) * | 2022-07-08 | 2023-12-08 | 浙江大学 | Fusion protein for targeted regulation of antigen-specific T cells and application thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102017115966A1 (en) * | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Polypeptide molecule with improved dual specificity |
-
2019
- 2019-08-02 DE DE102019121022.4A patent/DE102019121022A1/en active Pending
-
2020
- 2020-07-31 AR ARP200102162A patent/AR119549A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
DE102019121022A1 (en) | 2021-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7097923B2 (en) | Antigen binding construct for target molecule | |
EP3638700B1 (en) | Proteinaceous heterodimer and use thereof | |
PE20211284A1 (en) | ANTI-NKG2A ANTIBODIES AND USES OF THEM | |
RU2018139811A (en) | MULTI-SPECIFIC ANTI-BINDING CONSTRUCTIONS TARGETING IMMUNOTHERAPEUTIC MEANS | |
WO2016150899A3 (en) | Anti-ceacam6 antibodies and uses thereof | |
JP2016531100A5 (en) | ||
EA202091590A1 (en) | ANTIBODIES AGAINST PD-L1 AND THEIR APPLICATION OPTIONS | |
CO2022002044A2 (en) | Antigen-binding proteins that specifically bind mage-a | |
JP7341185B2 (en) | Antibodies against prostate-specific stem cell antigen and their uses | |
BR112022001902A2 (en) | Bispecific antigen-binding protein, isolated nucleic acid, recombinant host cell, pharmaceutical composition and method for producing the bispecific antigen-binding protein | |
RU2017114968A (en) | BINDING MOLECULES, AND EXACTLY ANTIBODIES, ABLE TO CONTACT L1CAM (CD171) | |
US11945863B2 (en) | CD33-, CD16- and CD123-specific single chain triplebody | |
PE20241177A1 (en) | MESOTHELIN BINDING PROTEINS AND USES THEREOF | |
AR119549A1 (en) | RECRUITMENT AGENT THAT ADDITIONALLY BINDS TO AN MHC MOLECULE | |
PE20240224A1 (en) | BISPECIFIC ANTI-TSPAN8/ANTI-CD3 ANTIBODY AND ANTI-TSPAN8 ANTIBODY | |
CA3220458A1 (en) | Compositions comprising a t cell redirection therapeutic and an anti-cd44 therapeutic | |
AR127360A1 (en) | MESOTHELIN BINDING PROTEINS AND USES THEREOF | |
AU2022241385A9 (en) | Anti-vaccinia virus antigen antibodies and related compositions and methods | |
AR125141A1 (en) | ANTI-ALPP / ALPPL2 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | |
NZ739252A (en) | Monoclonal antibodies against bcma | |
CA3070643A1 (en) | Mono and bispecific antibody binding to herg1 and herg1/integrin beta 1 | |
EA201990488A1 (en) | NEW T-CELL RECEPTORS AND IMMUNOTHERAPY WITH THEIR APPLICATION | |
NZ739252B2 (en) | Monoclonal antibodies against bcma |